Detailed Abstract
[BP Best Oral Presentation - Basic Research]
[BP BEST OP 4] The potential of KRAS mutation in circulating-tumor DNA as a marker for prognosis in patients with pancreatic cancer
Min Kyeong KIM1, Sang Myung WOO2, Boram PARK3, Hyeong Min PARK2, Kyong-Ah YOON4,5, Sung-Sik HAN2, Yoon Hee KIM6, Jungnam JOO3, Sun-Young KONG1, 7, 8, Sang-Jae PARK2
1Translational Cancer Research Branch, Division of Translational Science, National Cancer Center, Korea
2Center for Liver Cancer, National Cancer Center, Korea
3Biometric Research Branch, Division of Cancer Epidemiology and Prevention, National Cancer Center, Korea
4Cancer Genomics Branch, Division of Convergence Technology, National Cancer Center, Korea
5College of Veterinary Medicine, Konkuk University, Seoul, Korea
6Molecular Imaging & Therapy Branch, Division of Convergence Technology, National Cancer Cente, Korea
7Center for Hematologic Malignancy, National Cancer Center, Korea
8Department of Laboratory Medicine, Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center, Korea, Korea
Introduction : Circulating-tumor DNA (ctDNA) has been known to be released from tumor cells and investigated potential biomarkers for therapeutic responses. However, the role of ctDNA in pancreatic cancer has not been well studied. Here we selected KRAS mutation which has been known common over 95% of pancreatic ductal adenocarcinoma (PDA) and evaluated applicability as a prognostic marker through the quantitative analysis of ctDNA and KRAS mutation in the patients with PDA.
Methods : Total of 147 PDA patients were enrolled in the study. The concentration and fraction of KRAS mutation were measured by KRAS screening multiplex droplet digital PCR kit (Biorad, USA) in plasma. Median of ctDNA concentration, KRAS mutant concentration and fractional abundance were 425 ng/mL, 0.11 copies/uL and 0.35 %, respectively.
Results : KRAS mutant concentration and fractional abundance showed the association with poor survival in OS (P =0.007 and P
Conclusions : This study represents that KRAS mutant concentration and fractional abundance in ctDNA could be prognostic marker in pancreatic cancer.
Methods : Total of 147 PDA patients were enrolled in the study. The concentration and fraction of KRAS mutation were measured by KRAS screening multiplex droplet digital PCR kit (Biorad, USA) in plasma. Median of ctDNA concentration, KRAS mutant concentration and fractional abundance were 425 ng/mL, 0.11 copies/uL and 0.35 %, respectively.
Results : KRAS mutant concentration and fractional abundance showed the association with poor survival in OS (P =0.007 and P
Conclusions : This study represents that KRAS mutant concentration and fractional abundance in ctDNA could be prognostic marker in pancreatic cancer.
SESSION
BP Best Oral Presentation
Room B 3/30/2018 1:10 PM - 2:00 PM